Table 5.
Validation of SAPS II for 28-day and 60-month mortality according to the indication
| Overall (N = 65) | E-CPR (N = 35) | VA and V-AV (N = 20) | VV (N = 10) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Survivor (N = 31) | Death (N = 34) | p-value <0.001 | Survivor (N = 10) | Death (N = 25) | p-value 0.004 | Survivor (N = 11) | Death (N = 8) | p-value 0.005 | Survivor (N = 9) | Death (N = 1) | p-value 0.100 | |
| 28-day mortality | ||||||||||||
| SAPS II ≤80 | 22 (71.0) | 1 (2.9) | 5 (50.0) | 1 (4.0) | 8 (66.7) | 0 (0.0) | 9 (100.0) | 0 (0.0) | ||||
| SAPS II >80 | 9 (29.0) | 33 (97.1) | 5 (50.0) | 24 (96.0) | 4 (33.3) | 8 (100.0) | 0 (0.0) | 1 (100.0) | ||||
| 60-month mortality | ||||||||||||
| SAPS II ≤80 | 19 (79.2) | 4 (9.8) | 4 (66.7) | 2 (6.9) | 7 (70.0) | 1 (10.0) | 8 (100.0) | 1 (50.0) | ||||
| SAPS II >80 | 5 (20.8) | 37 (90.2) | 2 (33.3) | 27 (93.1) | 3 (30.0) | 9 (90.0) | 0 (0.0) | 1 (50.0) | ||||